InvestorsHub Logo
Followers 30
Posts 1475
Boards Moderated 0
Alias Born 07/10/2013

Re: None

Saturday, 10/17/2020 11:30:46 AM

Saturday, October 17, 2020 11:30:46 AM

Post# of 44690
Javitt knows a lot about public health policy because one of his professors chided him when he heard that the young medical student was going to India to help cure patients with glaucoma.
“All you’ll be doing is helping a blind beggar see,” the thoughtless man told Javitt. >>>>>>>>>>>>>>>

Enraged, Javitt conducted a study that proved that restoring eyesight to Indian patients with the eye disease increased their family earnings by 1,500%. The patient, now able to see, was able to work – and the pressure on his family to care for him was lifted, helping the entire family advance in life.

https://www.jpost.com/health-science/neurorx-on-the-cusp-of-releasing-a-life-saving-covid-19-treatment-644470

Multiple sclerosis (MS) is a disabling inflammatory, autoimmune demyelinating disease of the central nervous system (CNS). Despite intensive investigation, the mechanisms of disease pathogenesis remain unclear, and curative therapies are unavailable for MS. The current study describes a new possible strategy for the treatment of MS, based on the administration of the vasoactive intestinal peptide (VIP). Treatment with VIP significantly reduced incidence and severity of experimental autoimmune encephalomyelitis (EAE), an MS-related rodent model. VIP suppressed EAE neuropathology by reducing CNS inflammation and by selective blocking encephalitogenic T-cell reactivity, emerging as an attractive candidate for the treatment of human MS.

https://pubmed.ncbi.nlm.nih.gov/16888178/

Multiple Sclerosis Therapeutics Market To Reach USD 25.91 Billion By 2026 | Reports And Data

https://www.globenewswire.com/news-release/2019/12/03/1955908/0/en/Multiple-Sclerosis-Therapeutics-Market-To-Reach-USD-25-91-Billion-By-2026-Reports-And-Data.html

With an estimated lifetime cost per MS patient of over $4 million, MS is the second-ranked chronic condition (behind congestive heart failure) in direct all-cause medical costs. For the U.S., the total estimated cost of MS is $28 billion per year.

https://www.optum.com/business/resources/library/ms-cost-drivers.html